8-K: Inhibrx Updates Clinical Trials for Cancer Therapies

Inhibrx Biosciences provided progress updates on its INBRX-106 program for HNSCC and NSCLC, and its ozekibart program for colorectal cancer and Ewing sarcoma, with key data readouts and regulatory discussions anticipated in 2026.

Summary

• INBRX-106 Phase 2/3 trial for HNSCC: 46 of 60 patients recruited in Phase 2; enrollment expected to complete in Q1 2026.
• INBRX-106 Phase 1/2 trial for NSCLC: Enrollment of 34 patients completed in November 2025.
• Current INBRX-106 datasets for HNSCC and NSCLC lack sufficient maturity for interpretation; data expected to mature in H2 2026.
• Ozekibart Phase 1/2 expansion cohort for colorectal cancer: Enrollment of 44 patients completed in late October 2025.
• Ozekibart PFS data for colorectal cancer expected to mature in Q2 2026.
• Ozekibart Phase 1/2 trial for Ewing sarcoma: Enrollment expected to complete in Q2 2026.
• Inhibrx plans to meet with the FDA in H2 2026 to discuss an accelerated approval pathway for ozekibart in Ewing sarcoma, if current trends continue.
• A Biologics License Application (BLA) filing for ozekibart in chondrosarcoma is expected in early Q2 2026.

Sentiment

Score: 7

Explanation: The filing provides positive updates on enrollment completion for several trials and reiterates the potential for accelerated approval discussions for ozekibart in Ewing sarcoma and an upcoming BLA filing for chondrosarcoma. However, the lack of mature data for INBRX-106 and the distant timelines for key readouts temper immediate enthusiasm, making it a moderately positive but largely 'on track' update.

Positives

• Completed enrollment for INBRX-106 Phase 1/2 NSCLC trial (34 patients) in November 2025.
• Completed enrollment for ozekibart Phase 1/2 expansion cohort in colorectal cancer (44 patients) in late October 2025.
• Ozekibart in combination with FOLFIRI for colorectal cancer was previously reported as well tolerated, with durable responses and a high rate of disease control.
• Potential for accelerated approval pathway discussion with FDA for ozekibart in Ewing sarcoma in H2 2026, contingent on continued positive trends.
• BLA filing for ozekibart in chondrosarcoma expected in early Q2 2026, indicating significant progress towards commercialization for this indication.

Negatives

• Current datasets for INBRX-106 in HNSCC and NSCLC lack sufficient maturity to support an interpretation and conclusion on the viability of the program.
• Key data readouts for INBRX-106 are not expected until the second half of 2026, representing a significant waiting period for investors.

Risks

• Topline data may not accurately reflect complete results of a particular study or trial and remain subject to audit, and final data may differ materially from topline data.
• Uncertainty regarding the initiation, timing, progress, and results of preclinical studies and clinical trials, and research and development programs.
• Inability to advance therapeutic candidates into, and successfully complete, clinical trials.
• Interpretation of topline, interim, or preliminary data from clinical trials, including interpretations regarding disease control and disease response, may be inaccurate.
• Results from preclinical studies or early clinical trials not necessarily being predictive of future results.
• Unexpected adverse side effects or inadequate efficacy of therapeutic candidates that may limit their development, regulatory approval, and/or commercialization.
• Potential for programs and prospects to be negatively impacted by developments relating to competitors, including results of studies or regulatory determinations.
• Uncertainty regarding the timing or likelihood of regulatory filings and approvals and regulatory developments in the U.S. and foreign countries.
• Successful commercialization of therapeutic candidates, if approved, is not guaranteed.
• An accelerated development or approval pathway may not be available for therapeutic candidates and any such pathway may not lead to a faster development process.
• May not realize the benefits associated with orphan drug designation, including that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained.
• Uncertainty regarding the pricing, coverage, and reimbursement of therapeutic candidates, if approved.
• Inability to utilize its technology platform to generate and advance additional therapeutic candidates.

Future Outlook

Inhibrx anticipates significant clinical data readouts and regulatory interactions in 2026. This includes completing enrollment for INBRX-106 HNSCC and ozekibart Ewing sarcoma trials in Q1 and Q2 2026, respectively. Key data for INBRX-106 (HNSCC and NSCLC) is expected to mature in H2 2026, informing program viability. For ozekibart, PFS data for colorectal cancer is expected in Q2 2026, and a BLA filing for chondrosarcoma is anticipated in early Q2 2026. Furthermore, discussions with the FDA regarding an accelerated approval pathway for ozekibart in Ewing sarcoma are planned for H2 2026, provided current trends persist.

Management Comments

• The current datasets for both HNSCC and NSCLC lack sufficient maturity to support an interpretation and conclusion on the viability of this program.
• If the current response and duration trends observed continue, Inhibrx plans to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway for this indication [Ewing sarcoma].

Industry Context

The biopharmaceutical industry, particularly oncology, relies heavily on successful clinical trial progression and regulatory approvals. Inhibrx's updates reflect ongoing efforts in developing novel biologic therapeutic candidates, often in combination with established treatments like Keytruda (pembrolizumab), a common strategy to enhance efficacy in difficult-to-treat cancers. The pursuit of accelerated approval pathways, as mentioned for ozekibart in Ewing sarcoma, is a critical strategy for companies targeting rare or severe diseases to bring therapies to market faster. The BLA filing for chondrosarcoma indicates a significant step towards commercialization for that specific indication, positioning ozekibart as a potential new treatment option.

Comparison to Industry Standards

• The use of Keytruda (pembrolizumab) in combination therapies is a standard approach in oncology, reflecting industry trends to leverage established checkpoint inhibitors. Merck's Keytruda is a leading immunotherapy, and its inclusion in trials suggests Inhibrx is aligning with prevalent and effective treatment paradigms.
• The pursuit of an accelerated approval pathway for ozekibart in Ewing sarcoma, a rare and aggressive cancer, aligns with industry practices for orphan diseases where unmet medical needs are high. Companies like Blueprint Medicines (Ayvakit for systemic mastocytosis) or Sarepta Therapeutics (Exondys 51 for Duchenne muscular dystrophy) have successfully navigated accelerated approval pathways for rare conditions.
• The BLA filing for ozekibart in chondrosarcoma, following a successful single agent registration study, positions Inhibrx to potentially enter the market for a rare cancer, similar to how companies like Deciphera Pharmaceuticals (Qinlock for GIST) or Agios Pharmaceuticals (Tibsovo for AML) have brought targeted therapies to market for specific cancer types.

Stakeholder Impact

• Shareholders: Provides transparency on pipeline progress, which could influence investment decisions based on future potential. The BLA filing for ozekibart in chondrosarcoma and potential accelerated approval for Ewing sarcoma could be significant value drivers.
• Patients: Offers hope for new treatment options for various cancers, including HNSCC, NSCLC, colorectal cancer, and Ewing sarcoma, as trials progress.
• Employees: Continued progress in clinical development supports job security and the company's mission.
• Regulatory Authorities: Informs the SEC and FDA of ongoing clinical development and future regulatory intentions.

Next Steps

• Complete enrollment in INBRX-106 Phase 2 HNSCC trial in Q1 2026.
• File Biologics License Application (BLA) for ozekibart in chondrosarcoma in early Q2 2026.
• Provide an update on ozekibart PFS data for colorectal cancer in Q2 2026.
• Complete enrollment in ozekibart Phase 1/2 trial for Ewing sarcoma in Q2 2026.
• Data for INBRX-106 (HNSCC and NSCLC) expected to mature in H2 2026.
• Meet with the FDA in H2 2026 to discuss accelerated approval pathway for ozekibart in Ewing sarcoma (contingent on trends).

Key Dates

Recommendation

The filing presents a mixed but generally expected picture. While enrollment progress and the upcoming BLA filing for ozekibart in chondrosarcoma are positive, the lack of mature data for INBRX-106 and the H2 2026 timeline for key readouts mean significant catalysts are still some time away. The potential for accelerated approval in Ewing sarcoma is promising but conditional. Given the current stage of development and the inherent risks of clinical trials, a 'hold' recommendation is appropriate, awaiting more definitive efficacy data and regulatory outcomes before making a stronger directional call.

Keywords

Inhibrx Biosciences, INBX, clinical trial update, oncology, INBRX-106, Keytruda, HNSCC, head and neck squamous cell carcinoma, NSCLC, non-small cell lung cancer, ozekibart, INBRX-109, colorectal cancer, Ewing sarcoma, chondrosarcoma, FDA, accelerated approval, BLA filing, biopharmaceutical, cancer therapy